The combination of anti-angiogenesis agents and anti-PD-1/PD-L1 antibody has shown promising benefits in solid tumors such as hepatic carcinoma, renal cancer, and NSCLC (34). The gene discussed is CD274; the disease is hepatocellular carcinoma.